The NLRP3 inflammasome acts as the absolute first signal driving sterile inflammation triggered by internal damage signals such as oxidized lipids and cholesterol crystals. Because it is exclusively stimulated by these damage cues rather than pathogens, selectively inhibiting NLRP3 shuts down persistent sterile inflammatory damage while preserving the immune system's normal ability to recognize and respond to viral, fungal, and bacterial infections.
Chronic inflammation is readily measured in circulation, but pathological destruction occurs directly inside organ tissues, arterial walls, heart muscle, and the brain. Early NLRP3 inhibitors failed because limited bioavailability and restricted tissue access prevented them from altering tissue-level inflammation. Meaningful disease modification requires molecules engineered with high volume of distribution that rapidly transit out of the bloodstream and penetrate affected tissues.
To achieve high potency and safety, ravonoflast is engineered as a neutral molecule that freely crosses membranes and exits peripheral circulation. Once it enters specific culprit inflammatory cells—such as monocytes, macrophages, and microglia—concentrated intracellular enzymes clip a designed chemical catch. This transformation renders the drug polar, effectively trapping it inside these driver cells and amplifying local drug concentration relative to surrounding tissue.
Circulating biomarkers like hsCRP show general pathway engagement but cannot identify the specific node of inhibition or reflect local tissue inflammation status. Patients routinely exhibit normal systemic hsCRP despite suffering severe inflammation within the cardiac wall, brain, or liver on imaging. As development in sterile neuroinflammation and cardiology advances, drug developers must increasingly rely on imaging rather than blood tests for indication selection and pharmacodynamic proof.
Peripheral artery disease represents a potent Phase 3 proof of concept for cardiovascular anti-inflammatory therapeutics. Approximately 85% of the 20 million US PAD patients experience elevated residual inflammatory risk and suffer polyvascular complications in the heart and brain. Because no specific disease-modifying therapies have been approved for PAD pathobiology since 1999, the indication offers an enriched, underserved population to establish clinical proof across systemic vascular beds.
Targeting systemic versus neurological inflammatory indications requires distinct chemical scaffolds optimized for specific physiological compartments rather than a single universal molecule. Rezira segmented development into ravonoflast for systemic and macrophage-driven indications and trabzanoflast for the central nervous system. This approach allows developers to tailor drug distribution to specific biological barriers—such as the brain, eye, ear, and spinal cerebrospinal fluid—without compromising peripheral safety profiles.
